发明名称 RECOMBINANT MODIFIED SMALLPOX VIRUS, ITS USAGE (VERSIONS) AND CELL LINE INFECTED BY VIRUS (VERSIONS)
摘要 FIELD: biotechnology, immunobiotechnology. SUBSTANCE: invention relates to the development of recombinant modified smallpox virus Ankara (MVA) that is able to replicate in human cells. Virus MVA is used for preparing vaccine that is designated for animals and humans immunization. Cell lines infected with vector MVA-hTYP and MVA-LAInef, respectively, produce recombinant human tyrosinase, viral particles MVA-hTYP, recombinant protein Nef and viral particles MVA-LAInef. The prepared recombinant virus MVA is effective and absolutely safety expression vector that provides safety of vaccines and production of polypeptides. EFFECT: improved method of preparing, valuable medicinal properties. 23 cl, 9 dwg
申请公布号 RU2198217(C2) 申请公布日期 2003.02.10
申请号 RU19980101904 申请日期 1996.07.03
申请人 GSF-FORSHUNGSTSENTRUM FJUR UMVEL'T UND GEZUNDKHAJT;GMBKH 发明人 ZUTTER GERD;OL'MANN MARION;EHRFLE FOL'KER
分类号 C12N15/09;A61K31/00;A61K35/76;A61K39/00;A61K39/015;A61K39/04;A61K39/12;A61K39/145;A61K39/21;A61K39/245;A61K39/29;A61K48/00;A61P31/00;A61P31/12;A61P31/16;A61P31/18;A61P31/22;C07K14/16;C12N1/21;C12N5/10;C12N7/00;C12N7/01;C12N9/02;C12N9/12;C12N15/49;C12N15/53;C12N15/54;C12N15/63;C12N15/863;(IPC1-7):C12N7/01 主分类号 C12N15/09
代理机构 代理人
主权项
地址